You are using an older browser version. Please use a supported version for the best MSN experience.

ZIOPHARM ONCOLOGY, INC.

NASDAQ: ZIOP
2.51
-0.13
-4.92%

Sector

Healthcare

Industry

Biotechnology & Medical Research

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Key People

Laurence James Neil Cooper

Chief Executive Officer, Director

Kevin G. Lafond

Senior Vice President - Finance, Chief Accounting Officer, Treasurer

Lynn M. Ferrucci

Executive Vice President of Human Resources, Facilities, Administration and IT

Scott L. Tarriff

Independent Chairman of the Board

Elan Z. Ezickson

Independent Director

  • ZIOPHARM Oncology Inc

  • One First Avenue Parris Building 34,, Navy Yard Plaza

  • BOSTON, MA 02129

  • US.Map

  • Phone: +1 617 2591970

  • Fax: +1 617 2412855

  • ziopharm.com

Incorporated

2005

Employees

73

Insider Trades
  • Recent
  • All
  • Date

  • Name

  • Transaction

  • Shares

  • Price(s)

  • Value

    • 1/29/2020

    • LAFOND KEVIN G

    • Grant

    • 18,000

    • NA

    • NA

    • 1/29/2020

    • COOPER (LAURENCE JAMES NEIL)

    • Grant

    • 171,700

    • NA

    • NA

    • 1/29/2020

    • HADFIELD (ROBERT)

    • Grant

    • 59,100

    • NA

    • NA

    • 1/29/2020

    • SHUKLA SATH

    • Grant

    • 80,500

    • NA

    • NA

    • 1/29/2020

    • DE GROOT ELEANOR

    • Grant

    • 53,700

    • NA

    • NA

    • 1/29/2020

    • BUCK JILL

    • Grant

    • 53,700

    • NA

    • NA

    • 1/29/2020

    • MAUNEY DAVID M. M.D.

    • Grant

    • 80,500

    • NA

    • NA

    • 1/2/2020

    • LAFOND KEVIN G

    • Sold

    • 21,570

    • 4.55

    • 98,143.50

    • 1/2/2020

    • HADFIELD (ROBERT)

    • Sold

    • 16,853

    • 4.55

    • 76,681.15

    • 1/2/2020

    • MAUNEY DAVID M. M.D.

    • Sold

    • 22,394

    • 4.55

    • 101,892.70

    • 1/2/2020

    • BUCK JILL

    • Sold

    • 27,923

    • 4.55

    • 127,049.65

    • 1/2/2020

    • DE GROOT ELEANOR

    • Sold

    • 24,890

    • 4.55

    • 113,249.50

    • 12/31/2019

    • EZICKSON ELAN

    • Grant

    • 31,780

    • NA

    • NA

    • 12/31/2019

    • PAGAN (DOUGLAS W)

    • Grant

    • 15,890

    • NA

    • NA

    • 12/31/2019

    • HAGEN HEIDI

    • Grant

    • 31,780

    • NA

    • NA

    • 12/31/2019

    • BRAUNSTEIN (SCOTT N. M.D.)

    • Grant

    • 31,780

    • NA

    • NA

    • 12/30/2019

    • COOPER (LAURENCE JAMES NEIL)

    • Sold

    • 110,694

    • 4.88

    • 540,186.72

    • 12/27/2019

    • COOPER (LAURENCE JAMES NEIL)

    • NA

    • 44,642

    • 2.24

    • 99,998.08

    • 11/26/2019

    • LAFOND KEVIN G

    • Sold

    • 11,667

    • 5.25

    • 61,251.75

    • 11/26/2019

    • LAFOND KEVIN G

    • NA

    • 11,667

    • 2.85

    • 33,250.95

    • Date

    • Name

    • Transaction

    • Shares

    • Price(s)

    • Value

      • 1/29/2020

      • LAFOND KEVIN G

      • Grant

      • 18,000

      • NA

      • NA

      • 1/29/2020

      • COOPER (LAURENCE JAMES NEIL)

      • Grant

      • 171,700

      • NA

      • NA

      • 1/29/2020

      • HADFIELD (ROBERT)

      • Grant

      • 59,100

      • NA

      • NA

      • 1/29/2020

      • SHUKLA SATH

      • Grant

      • 80,500

      • NA

      • NA

      • 1/29/2020

      • DE GROOT ELEANOR

      • Grant

      • 53,700

      • NA

      • NA

      • 1/29/2020

      • BUCK JILL

      • Grant

      • 53,700

      • NA

      • NA

      • 1/29/2020

      • MAUNEY DAVID M. M.D.

      • Grant

      • 80,500

      • NA

      • NA

      • 1/2/2020

      • LAFOND KEVIN G

      • Sold

      • 21,570

      • 4.55

      • 98,143.50

      • 1/2/2020

      • HADFIELD (ROBERT)

      • Sold

      • 16,853

      • 4.55

      • 76,681.15

      • 1/2/2020

      • MAUNEY DAVID M. M.D.

      • Sold

      • 22,394

      • 4.55

      • 101,892.70

      • 1/2/2020

      • BUCK JILL

      • Sold

      • 27,923

      • 4.55

      • 127,049.65

      • 1/2/2020

      • DE GROOT ELEANOR

      • Sold

      • 24,890

      • 4.55

      • 113,249.50

      • 12/31/2019

      • EZICKSON ELAN

      • Grant

      • 31,780

      • NA

      • NA

      • 12/31/2019

      • PAGAN (DOUGLAS W)

      • Grant

      • 15,890

      • NA

      • NA

      • 12/31/2019

      • HAGEN HEIDI

      • Grant

      • 31,780

      • NA

      • NA

      • 12/31/2019

      • BRAUNSTEIN (SCOTT N. M.D.)

      • Grant

      • 31,780

      • NA

      • NA

      • 12/30/2019

      • COOPER (LAURENCE JAMES NEIL)

      • Sold

      • 110,694

      • 4.88

      • 540,186.72

      • 12/27/2019

      • COOPER (LAURENCE JAMES NEIL)

      • NA

      • 44,642

      • 2.24

      • 99,998.08

      • 11/26/2019

      • LAFOND KEVIN G

      • Sold

      • 11,667

      • 5.25

      • 61,251.75

      • 11/26/2019

      • LAFOND KEVIN G

      • NA

      • 11,667

      • 2.85

      • 33,250.95

      AdChoices
      AdChoices
      AdChoices
      image beaconimage beaconimage beacon